



HAL
open science

Adult human liver slice cultures: Modelling of liver fibrosis and evaluation of new anti-fibrotic drugs

Kartasheva-Ebertz Daria, Gaston Jesintha, Loriane Lair-Mehiri, Pierre-Philippe Massault, Olivier Scatton, Jean-Christophe Vaillant, Vladimir Alexei Morozov, Stanislas Pol, Sylvie Lagaye

► **To cite this version:**

Kartasheva-Ebertz Daria, Gaston Jesintha, Loriane Lair-Mehiri, Pierre-Philippe Massault, Olivier Scatton, et al.. Adult human liver slice cultures: Modelling of liver fibrosis and evaluation of new anti-fibrotic drugs. World journal of hepatology, 2021, World Journal of Hepatology, 13 (2), pp.187-217. 10.4254/wjh.v13.i2.187 . hal-03366163

HAL Id: hal-03366163

<https://hal.science/hal-03366163v1>

Submitted on 21 Jan 2022

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Distributed under a Creative Commons Attribution - NonCommercial 4.0 International License

World Journal of *Hepatology*

World J Hepatol 2021 February 27; 13(2): 162-269



EDITORIAL

- 162 Meeting report of the editorial board meeting for *World Journal of Hepatology* 2021
Ma L, Li X

REVIEW

- 166 Extrahepatic cholangiocarcinoma: Current status of endoscopic approach and additional therapies
Tantau AI, Mandrutiu A, Pop A, Zaharie RD, Crisan D, Preda CM, Tantau M, Mercea V

ORIGINAL ARTICLE**Basic Study**

- 187 Adult human liver slice cultures: Modelling of liver fibrosis and evaluation of new anti-fibrotic drugs
Kartasheva-Ebertz D, Gaston J, Lair-Mehiri L, Massault PP, Scatton O, Vaillant JC, Morozov VA, Pol S, Lagaye S

Clinical and Translational Research

- 218 Production and activity of matrix metalloproteinases during liver fibrosis progression of chronic hepatitis C patients
Martinez-Castillo M, Hernandez-Barragan A, Flores-Vasconcelos I, Galicia-Moreno M, Rosique-Oramas D, Perez-Hernandez JL, Higuera-De la Tijera F, Montalvo-Jave EE, Torre-Delgadillo A, Cordero-Perez P, Muñoz-Espinosa L, Kershenobich D, Gutierrez-Reyes G

EVIDENCE-BASED MEDICINE

- 233 Awareness of non-alcoholic steatohepatitis and treatment guidelines: What are physicians telling us?
Wessels DH, Rosenberg Z

META-ANALYSIS

- 242 Occult hepatitis C virus infection in the Middle East and Eastern Mediterranean countries: A systematic review and meta-analysis
Hedayati-Moghaddam MR, Soltanian H, Ahmadi-Ghezeldasht S

CASE REPORT

- 261 Two-stage hepatectomy with radioembolization for bilateral colorectal liver metastases: A case report
Serenari M, Neri J, Marasco G, Larotonda C, Cappelli A, Ravaioli M, Mosconi C, Golfieri R, Cescon M

ABOUT COVER

Editorial Board member of *World Journal of Hepatology*, Dr. Aurelio Sonzogni is Senior Pathologist at Papa Giovanni XXII Hospital in Bergamo, Italy, a tertiary care institution focused on care of terminal organ dysfunction, mainly kidney and liver. Having received his MD from University of Milan in 1985, Dr. Sonzogni undertook his postgraduate training in Surgical Pathology at Milan University, receiving his Master's degree in 1988. After serving as Assistant Pathologist since 1987, he rose to Senior Pathologist in 1992 in the Gastroenterology and Liver Pathology Section of Bergamo Hospital and has held the position since. His ongoing research interests are digestive, liver and kidney non-neoplastic diseases, particularly involving transplantation pathology and pediatric pathology.

AIMS AND SCOPE

The primary aim of *World Journal of Hepatology (WJH, World J Hepatol)* is to provide scholars and readers from various fields of hepatology with a platform to publish high-quality basic and clinical research articles and communicate their research findings online.

WJH mainly publishes articles reporting research results and findings obtained in the field of hepatology and covering a wide range of topics including chronic cholestatic liver diseases, cirrhosis and its complications, clinical alcoholic liver disease, drug induced liver disease autoimmune, fatty liver disease, genetic and pediatric liver diseases, hepatocellular carcinoma, hepatic stellate cells and fibrosis, liver immunology, liver regeneration, hepatic surgery, liver transplantation, biliary tract pathophysiology, non-invasive markers of liver fibrosis, viral hepatitis.

INDEXING/ABSTRACTING

The *WJH* is now abstracted and indexed in PubMed, PubMed Central, Emerging Sources Citation Index (Web of Science), Scopus, China National Knowledge Infrastructure (CNKI), China Science and Technology Journal Database (CSTJ), and Superstar Journals Database. The *WJH's* CiteScore for 2019 is 5.8 and Scopus CiteScore rank 2019: Hepatology is 22/61.

RESPONSIBLE EDITORS FOR THIS ISSUE

Production Editor: *Li-Li Wang*; Production Department Director: *Xiang Li*; Editorial Office Director: *Xiang Li*.

NAME OF JOURNAL

World Journal of Hepatology

ISSN

ISSN 1948-5182 (online)

LAUNCH DATE

October 31, 2009

FREQUENCY

Monthly

EDITORS-IN-CHIEF

Nikolaos Pylsopoulos, Ke-Qin Hu, Koo Jeong Kang

EDITORIAL BOARD MEMBERS

<https://www.wjgnet.com/1948-5182/editorialboard.htm>

PUBLICATION DATE

February 27, 2021

COPYRIGHT

© 2021 Baishideng Publishing Group Inc

INSTRUCTIONS TO AUTHORS

<https://www.wjgnet.com/bpg/gerinfo/204>

GUIDELINES FOR ETHICS DOCUMENTS

<https://www.wjgnet.com/bpg/GerInfo/287>

GUIDELINES FOR NON-NATIVE SPEAKERS OF ENGLISH

<https://www.wjgnet.com/bpg/gerinfo/240>

PUBLICATION ETHICS

<https://www.wjgnet.com/bpg/GerInfo/288>

PUBLICATION MISCONDUCT

<https://www.wjgnet.com/bpg/gerinfo/208>

ARTICLE PROCESSING CHARGE

<https://www.wjgnet.com/bpg/gerinfo/242>

STEPS FOR SUBMITTING MANUSCRIPTS

<https://www.wjgnet.com/bpg/GerInfo/239>

ONLINE SUBMISSION

<https://www.f6publishing.com>

Basic Study

Adult human liver slice cultures: Modelling of liver fibrosis and evaluation of new anti-fibrotic drugs

Daria Kartasheva-Ebertz, Jesintha Gaston, Loriane Lair-Mehiri, Pierre-Philippe Massault, Olivier Scatton, Jean-Christophe Vaillant, Vladimir Alexei Morozov, Stanislas Pol, Sylvie Lagaye

ORCID number: Daria Kartasheva-Ebertz 0000-0001-9509-0253; Jesintha Gaston 0000-0003-4716-7409; Loriane Lair-Mehiri 0000-0003-4428-8272; Pierre-Philippe Massault 0000-0002-4728-3816; Olivier Scatton 0000-0001-8313-3500; Jean-Christophe Vaillant 0000-0003-0563-120X; Vladimir Alexei Morozov 0000-0001-7013-7115; Stanislas Pol 0000-0001-9772-9591; Sylvie Lagaye 0000-0002-9156-3698.

Author contributions: Kartasheva-Ebertz D, Gaston J, Lair-Mehiri L, Morozov VA, Pol S, and Lagaye S were responsible for the overall study design; Massault PP, Scatton O, Vaillant JC, and Pol S selected and contributed patients' samples; Kartasheva-Ebertz D, Gaston J, Lair-Mehiri L, and Lagaye S performed experiments; Kartasheva-Ebertz D, Morozov VA, Pol S, and Lagaye S analyzed and interpreted the data; Kartasheva-Ebertz D, Morozov VA, Pol S, and Lagaye S contributed to the writing of the manuscript, discussed and refined the manuscript.

Supported by the Institut National de la Santé et de la Recherche Médicale (INSERM, France) and by Institut Pasteur (Paris, France); Daria Kartasheva-Ebertz received a PhD Fellowship from Assistance

Daria Kartasheva-Ebertz, Jesintha Gaston, Loriane Lair-Mehiri, Stanislas Pol, Sylvie Lagaye, Institut Pasteur, Immunobiologie des Cellules Dendritiques, INSERM U1223, Paris 75015, France

Daria Kartasheva-Ebertz, Jesintha Gaston, Loriane Lair-Mehiri, BioSPC, Université de Paris, Paris 75005, France

Pierre-Philippe Massault, Service de Chirurgie digestive, Hépato-biliaire et Endocrinienne, AP-HP, Groupe Hospitalier Cochin, Paris 75014, France

Olivier Scatton, Jean-Christophe Vaillant, Service de Chirurgie digestive et Hépato bilio pancréatique, AP-HP, Groupe Hospitalier La Pitié-Salpêtrière, Médecine Sorbonne Université, Paris 75013, France

Vladimir Alexei Morozov, Center for HIV and Retrovirology, Department of Infectious Diseases, Robert Koch Institute, Berlin 13353, Germany

Stanislas Pol, Département d'Hépatologie, AP-HP, Groupe Hospitalier Cochin, Université de Paris, Paris 75014, France

Corresponding author: Sylvie Lagaye, DSc, PhD, Senior Scientist, Institut Pasteur, Immunobiologie des Cellules Dendritiques, INSERM U1223, 25-28 rue du Dr Roux, Paris 75015, France. sylvie.lagaye@inserm.fr

Abstract

BACKGROUND

Liver fibrosis can result in end-stage liver failure and death.

AIM

To examine human liver fibrogenesis and anti-fibrotic therapies, we evaluated the three dimensional *ex vivo* liver slice (LS) model.

METHODS

Fibrotic liver samples (F0 to F4 fibrosis stage according to the METAVIR score) were collected from patients after liver resection. Human liver slices (HLS) were cultivated for up to 21 days. Hepatitis C virus (HCV) infection, alcohol (ethanol stimulation) and steatosis (palmitate stimulation) were examined in fibrotic (F2 to

Publique-Hôpitaux de Paris (AP-HP, France).

Institutional review board

statement: An institutional review board statement is not required for manuscript submission in our Institution.

Conflict-of-interest statement: No conflict of interest to declare indicated in the manuscript.

Data sharing statement: No data sharing.

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

Manuscript source: Invited manuscript

Specialty type: Gastroenterology and hepatology

Country/Territory of origin: France

Peer-review report's scientific quality classification

Grade A (Excellent): 0
Grade B (Very good): 0
Grade C (Good): C
Grade D (Fair): 0
Grade E (Poor): 0

Received: August 27, 2020

Peer-review started: August 26, 2020

First decision: October 21, 2020

Revised: November 4, 2020

Accepted: December 30, 2020

Article in press: December 30, 2020

Published online: February 27, 2021

P-Reviewer: Balaban YH

S-Editor: Zhang L

L-Editor: A

F4) liver slices infected (or not) with HCV. F0-F1 HLS were used as controls. At day 0, either ursodeoxycholic acid (choleretic and hepatoprotective properties) and/or α -tocopherol (antioxidant properties) were added to standard of care on HLS and fibrotic liver slices, infected (or not) with HCV. Expression of the biomarkers of fibrosis and the triglyceride production were checked by quantitative reverse transcription polymerase chain reaction and/or enzyme-linked immunosorbent assay.

RESULTS

The cultures were viable *in vitro* for 21 days allowing to study fibrosis inducers and to estimate the effect of anti-fibrotic drugs. Expression of the biomarkers of fibrosis and the progression to steatosis (estimated by triglycerides production) was increased with the addition of HCV and /or ethanol or palmitate. From day 15 of the follow-up studies, a significant decrease of both transforming growth factor β -1 and Procol1A1 expression and triglycerides production was observed when a combined anti-fibrotic treatment was applied on HCV infected F2-F4 LS cultures.

CONCLUSION

These results show that the human three dimensional *ex vivo* model effectively reflects the *in vivo* processes in damaged human liver (viral, alcoholic, nonalcoholic steatohepatitis liver diseases) and provides the proof of concept that the LS examined model permits a rapid evaluation of new anti-fibrotic therapies when used alone or in combination.

Key Words: Human liver fibrosis; Hepatitis C virus; Alcoholic liver disease; Nonalcoholic steatohepatitis; *Ex vivo* model; Drugs

©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.

Core Tip: In the developed world, about 45% of deaths are due to fibroproliferative diseases. Liver fibrosis is frequently associated with viral infection (Hepatitis C virus and Hepatitis B virus infection), chronic inflammation and excessive alcohol consumption. Despite the availability of effective antiviral drugs, morbidity, and mortality related to viral hepatitis are still increasing. Moreover, the number of non-viral liver diseases such as nonalcoholic steatohepatitis, and alcoholic liver disease is steadily growing. Our studies provide the proof of concept that the three-dimensional *ex vivo* model of human liver slice culture can be used for the molecular investigation of fibrosis as well as to perform follow-up studies of new anti-fibrotic drugs and therapies for a 21-days period.

Citation: Kartasheva-Ebertz D, Gaston J, Lair-Mehiri L, Massault PP, Scatton O, Vaillant JC, Morozov VA, Pol S, Lagaye S. Adult human liver slice cultures: Modelling of liver fibrosis and evaluation of new anti-fibrotic drugs. *World J Hepatol* 2021; 13(2): 187-217

URL: <https://www.wjgnet.com/1948-5182/full/v13/i2/187.htm>

DOI: <https://dx.doi.org/10.4254/wjh.v13.i2.187>

INTRODUCTION

Forty five percent of deaths in the developed countries may be attributed to fibroproliferative diseases^[1]. Liver fibrosis is frequently associated with viral infection [Hepatitis C virus (HCV) and Hepatitis B virus (HBV)] infection, chronic inflammation, and excessive alcohol consumption. Despite effective antiviral treatment, morbidity and hepatitis-related mortalities are still increasing. Moreover, the number of non-viral liver diseases such as nonalcoholic steatohepatitis (NASH) and alcoholic liver disease (ALD) is steadily growing^[2].

Progression to liver fibrosis is a multistep process, whose development time varies. Fibrosis is initiated by the activation of hepatic stellate cells triggered by several signaling pathways^[3]. The activation of stellate cells induces cellular matrix production

P-Editor: Wang LL



and collagen 1 expression This process is stimulated by transforming growth factor- β 1 (TGF- β 1), which is a crucial element involved in fibrogenesis^[4]. The progression of liver fibrosis frequently results in cirrhosis (liver acini are substituted by regeneration nodules surrounded by fibrosis) and, further on, in the development of hepatocellular carcinoma. Liver fibrosis can persist even with effective treatments. In most cases, the necro-inflammation leading to fibrosis can be effectively treated by treatments with antiviral drugs that target HCV, by nucleoside analogs in patients with HBV, by immune suppression in autoimmune hepatitis, by ethanol weaning and other dietary approaches in ALD and NASH, and iron chelation for hemochromatosis. However, if patients are not treated in a timely manner, and fibrosis progresses to decompensated cirrhosis, the only remaining option is liver transplantation The main obstacles (or delays) to liver transplantation are an insufficient number or a shortage of suitable organs, long waiting lists and high cost of this procedure^[5]. Thus, mortality remains high in patients on the waiting list and new anti-fibrotic agents and new clinical strategies to manage patients in the different stages of liver fibrosis are needed.

The liver slices (LS) cultures are appropriate models to study liver fibrosis, because they maintain the complex cellular interactions that occur *in vivo*, which cannot be obtained in co-cultures systems^[6]. These cultures can be used to study molecular biological events either in the fibrotic liver tissue or in hepatocellular carcinoma tissue. Although the LS cultures from non-fibrotic and fibrotic rat livers have been used to investigate the early and late phases as well as the resolution of liver fibrosis^[7,8], the experiments are limited to 3 days in the rat model^[7-9], and to 15 days in the human non-fibrotic LS model^[10]. In previous studies, we developed a three dimensional (3D) *ex vivo* model of HCV replication using human LS cultures that were followed for 10 days^[11] to evaluate a new antiviral drug^[12].

Here, for the first time, human fibrotic LS cultures (stages F2-F4) were successfully maintained and evaluated for 21 days. Using the *ex vivo* LS model for a 21-d period makes it possible to explore molecular fibrogenesis in more detail including the role of important factors such as HCV infection, ethanol (EtOH), or steatosis. Thus, this model can improve the understanding of the three of the main causes of liver injury in clinical practice^[2]. In addition, it was demonstrated that LS cultures are efficient instruments to study anti-fibrotic drugs and their combination^[13,14].

This study provides the proof of concept that the *ex vivo* model of human LS culture can be used for the molecular evaluation of fibrosis and to perform follow-up studies of new anti-fibrotic drugs and therapies for a 21-days period.

MATERIALS AND METHODS

Patients and human liver tissue specimens

Adult human liver tissue samples were obtained from selected patients with different liver pathologies, as previously described^[11,12]. Written informed consent was obtained from each patient included in the study and the study protocol conforms to the ethical guidelines of the 1975 Declaration of Helsinki as reflected in a priori approval by the institution's human research committee. Experimental procedures were carried out in accordance with French laws and Regulations and ethic committees from Pitié-Salpêtrière Hospital, Cochin Hospital, and Pasteur Institute (France). The tissue samples from twenty patients were divided into three groups according to their METAVIR score^[15]. Liver samples were either non-fibrotic F0-F1, obtained during surgery for colorectal cancer liver metastases or fibrotic ranging from F2 to F4 according to the METAVIR score (Table 1). Significant necrotic inflammation as defined by an activity grade (A) was not always available.

Liver slices preparation, culture and infection

We obtained between 32 to 48 liver slices for each donor sample. On the different days of the kinetic experiments, the results were obtained from the mean of three liver slices from each donor. The liver slices were infected with a same viral stock. The liver slice cultures were inoculated with viral supernatant diluted in fresh medium, at MOI = 0.1 (multiplicity of infection) and incubated overnight at 37 °C. In order to remove free virus, the slices were washed three times with phosphate-buffered saline (PBS) and fresh complete culture medium was added, after which cultures were followed in the absence of additional changes to the media composition or replacement with fresh culture medium. The preparation and culture of the liver slices, HCV RNA transfection, virus production, HCV RNA extraction were performed as previously described^[11,12].

Table 1 METAVIR scores and description of clinical liver samples

METAVIR score		Patients (n)	Pathology
F0-F1	No fibrosis or mild fibrosis	10	HBV-, HCV-, HIV-seronegative patients who underwent liver resection surgery, mainly for liver metastasis, in the absence of underlying liver disease. A0-F1
F0-F1	No fibrosis or mild fibrosis	1	Prior history: Breast cancer with liver metastases, treated by surgery and radio-chemotherapy. Non-tumoral liver sample: Perisinusoidal and portal fibrosis without septa (F1). No steatosis
		2	Prior history: HCV infection, resected hepatocellular carcinoma. Non tumoral liver samples: A0F0
F2-F3	Moderate to severe fibrosis	2	Cholangiocarcinoma, non-tumor liver samples
		1	Chronic hepatitis B infection, NASH, and two resected hepatocellular carcinoma nodules. Non-tumoral liver sample: Chronic hepatitis with extensive fibrosis A1F3
F4	Cirrhosis	2	HCC, non-tumor liver samples
		1	HCC, treated HCV infection. Non-tumoral liver sample
		1	HCC on untreated HCV infection. Non-tumoral liver sample

A “significant” fibrosis, as defined by a fibrosis grade (F), is greater than 1 by the METAVIR scoring system, with usually a significant necrotic inflammation as defined by an activity grade (A) greater than 1 by the METAVIR scoring system. Fibrosis grade: F0: No fibrosis, F1: Portal fibrosis without septa, F2: Portal fibrosis with few septa, F3: Numerous septa without cirrhosis, F4: Cirrhosis. Activity grade: A0: No activity, A1: Mild activity, A2: Moderate activity, A3: Severe activity. HBV: Hepatitis B virus; HCV: Hepatitis C virus; HCC: Hepatocellular carcinoma; HIV: Human immunodeficiency virus; NASH: Nonalcoholic steatohepatitis.

Liver slices viability

Special attention was paid to the condition of clinical liver samples. It is evident that the condition of the liver sections that we obtained was different. Thus, they were carefully selected for *in vitro* studies. In fact, cell viability was estimated by determining the percentage of viable cells upon microscopic examination 10X, using live/dead fixable dead cell stain kit (Molecular Probes, Invitrogen, ThermoFisher, France) and, as the percentage of ATP production determined by enzyme-linked immunosorbent assay (ELISA) assays, while observing the increasing albumin and urea secretion levels throughout the experiments, which indicates that the physiological and biochemical parameters of the liver slices are normal. On day 15, the immunostaining for Ki67, a cellular marker for proliferation confirmed the cell viability. Only slices with viability greater than 80% were used and allowed to obtain all the presented results. The architecture of human LS cultures was accessed by hematoxylin-eosin (HE) staining performed as following: Cryosections were washed with distilled water for 5-10 min and then stained for 8 min with hematoxylin, followed by a washing step with warm water at 30 °C for 10 min. After a short washing step with distilled water, the slices were counter-stained for 6 min with eosin. Washing was followed by dehydration steps in 2 min intervals in 50%, 60%, 70%, 80% and 90% of ethanol.

Experimental set up

The experimental set up was as follows (Figure 1). Non-infected liver slices obtained either from human non-fibrotic (F0-F1) or fibrotic (F2-F3, F4) liver resection and cut in 350 µm-thick slices (approximately 2.7×10^6 cells per slice), were cultivated for up to 21 days either with or without HCV, ethanol (EtOH) (1 mmol/L, 5 mmol/L, 25 mmol/L) or palmitate (500 µmol/L). Liver slices were infected with hepatitis C virus infection from cell culture (HCVcc) supernatant [Con1/C3 (genotype1b)]^[16] (MOI = 0.1) (INF LS) in presence or not either of EtOH (1 mmol/L, 5 mmol/L, 25 mmol/L) or palmitate (500 µmol/L). The different concentrations of EtOH were added on days 0, 5, 10, 15 during the kinetic studies. Palmitate (500 µmol/L) was added or not to non-infected and infected liver slices on days 0, 5, 10 and 15 of the kinetic studies. As previously described, infectivity (ffu/mL) was measured on days 1, 5, 10, and 21 post-treatment depending on the experiment^[11,12]. All experiments were performed in triplicate. All data were presented in relation to the percentage of viable liver slices in culture. Once the model was validated for the presence of “molecular fibrogenesis” defined as a significant increase in fibrosis biomarkers [TGF-β1, Hsp47, α-SMA, Procol1A1, matrix




Figure 1 Experimental set up of the different liver slice treatments during the cultures. NINFLS: Non-infected liver slices; EtOH: Ethanol; LS: Liver slices; Toco: Tocopherol; UCDA: Ursodeoxycholic acid; HCV: Hepatitis C virus.

metalloproteinases 2 (MMP-2), MMP-9, and vascular endothelial growth factor (VEGF)], we evaluated the anti-fibrotic properties of two drugs, ursodeoxycholic acid (UCDA) (Sigma-Aldrich, Merck, Germany) and α -Tocopherol (Toco) (Sigma-Aldrich, Merck, Germany). UCDA (240 ng/liver slice) and / or α -Toco (170 ng/liver slice) were added to the culture media from day 0 and every day up to day 20 of the culture. The estimation of the triglyceride content was essential during the different kinetic experiments, since its accumulation in the cytoplasm of hepatocytes indicates cell metabolism disturbances, typical of non-alcoholic fatty liver disease^[17].

Quantification of HCV RNA and liver-specific and fibrosis markers genes expression by real-time reverse transcription-quantitative polymerase chain reaction

The liver slices were washed three times in PBS at 4 °C. RNA was extracted from three combined slices using Trizol reagent as described in the protocol (Invitrogen, Cergy Pontoise, France). A strand-specific real-time reverse transcription-quantitative polymerase chain reaction (RT-qPCR) technique to quantify the intracellular levels of positive and negative-strand HCV RNA was performed during the experiments with the quantification of 28S rRNA used as an internal standard to quantify HCV in total liver RNA as previously described^[11], (detection threshold: 25 copies/reaction). Briefly, reverse transcription was performed using an oligo primer and Moloney murine leukemia virus reverse transcriptase (Promega, Charbonnières, France) according to the manufacturer's instructions. Real-time polymerase chain reactions were performed using Light CyclerR (Roche Applied Science, Grenoble, France) and FastStart DNA Master SYBR Green I kit (Roche Applied Science, Grenoble, France) according to the manufacturer's instructions.

The relative expression of each liver-specific transcript (albumin, HNF-1 β , HNF-4 α transcription factors, cytochrome P450 enzymes, CYP2E1 and CYP3A4) was quantified by qRT-PCR and normalized to 18S RNA transcripts^[11,12]. The relative expression level of the transcripts was then determined in relation to the 18S RNA by the (Ct) method^[13]. The PCR conditions were as follows: Denaturation for 10 min at 95 °C, followed by 45 cycles of denaturation at 95 °C for 5 s, annealing at 60 °C for 20 s, and elongation at 72 °C for 30 s. The specificity of the PCR products was checked by a melting curve analysis after amplification. Primer sequences are listed in Table 2.

The expression of fibrosis markers in either non-infected liver slices (used as controls, CTRL) or in HCV-infected (INF) liver slices with or without the presence of EtOH or palmitate were evaluated by RT-qPCR with the SYBR PrimeScript RT-qPCR Kit (TaKaRa Bio Inc., Japan) and performed with the housekeeping gene, GAPDH as an internal control. Real-Time qPCR reaction for fibrosis markers including TGF- β 1, heat shock protein 47 (Hsp47), alpha smooth muscle actin (β -SMA), procollagen1 A1 (Procol1A1), and VEGF was performed as follows: Denaturation for 10 min at 95 °C followed by 45 cycles of denaturation at 95 °C for 15 s, annealing at 60 °C for 1 min, and elongation at 72 °C for 30 s. Concerning the MMP-2, MMP-9 gene expression, the Real-Time qPCR reaction was performed as follows: Denaturation for 10 min at 95 °C followed by 45 cycles of denaturation at 95 °C for 15 s, annealing at 60 °C and 68 °C

Table 2 Primers used for real-time reverse transcription-quantitative polymerase chain reaction analysis

Gene	Forward primer sequence	Reverse primer sequence
<i>CYP2E1</i>	AGCACAAACTCTGAGATATGG	ATAGTCACIGTACTTGAAC
<i>CYP3A4</i>	GCCTGGTGCTCCTCTATCTA	ACAGGCTGTTGACCATCATAAAAAG
<i>HNF-1β</i>	ACGTCAGAAAAGCAACGAGAGATC	CCCAGGCCCATGGCT
<i>HNF-4α</i>	CCTGGAATTTGAGAATGTGCAG	AGGTTGGTGCCTTCTGATGG
<i>Albumin</i>	ATGAGATGCCTGCTGACTTG	GCACGACAGAGTAATCAGGA
<i>18S RNA</i>	CAGAGCGAAAGCATTGCCAAG	CGGCATCGTTTATGGTCGGAAC
<i>TGF-β1</i>	CCTGGAAAGGGCTCAACAC	CAGTCTTCTCTGTGGAGCTGA
<i>HSP 47</i>	GCCACCGTGGTGCCGA	GCCAGGGCCGCCTCCAGGAG
<i>β-SMA</i>	AGGGGGTGATGGGTGGGAA	ATGATGCCATGTTCTATCGG
<i>Procol1A1</i>	CAATCACCTGCGTACAGAACGCC	CGGCAGGGCTCGGGTTTC
<i>MMP-2</i>	CTT CGCCCC AGG CAC TGG TG	CCTCGCTCCCATGGG GTT CCGT
<i>MMP-9</i>	GGT CCCCCACT GCT GGC CCTTCTACGGCC	GTCTCAGG GCACTG GAG GAT GTC ATA GCT
<i>VEGF</i>	TACCTCCACCATGCCAAGTG	ATGATTCTGCCCTCCTCCTTC
<i>GAPDH</i>	ACCAGGGCTGCTTTAACTCT	GGTGCCATGGAATTGGC

respectively, for 1 min, and elongation at 72 °C for 30 s. Ct (threshold cycle) values were corrected for the Ct values of the housekeeping gene GAPDH. Primer sequences are listed in [Table 2](#).

Albumin enzyme-linked immunosorbent assay: Human liver albumin concentrations were determined by a competitive ELISA as previously described^[18,19]. Purified human albumin and peroxidase-conjugated anti-human albumin were obtained from MP Biomedicals Europe (Illkirch, France). To ensure the specificity of the ELISA, human antibodies were incubated for 2 h at 37 °C with 3% BSA in 0.5% Tween-20 in PBS before the sample addition in order to block any cross reaction.

Urea assays: Urea concentrations were determined by colorimetric assay (640-1, Sigma-Aldrich) according to the manufacturer's recommendations and analyzed with BioPhotometer 6131 (Eppendorf, Hamburg, Germany).

Western blotting and antibodies

Western blotting was performed as previously described^[11,12], and the antibodies used are described as following. Mouse monoclonal antibodies (mAbs) to HCV core protein (C7-50; dilution 1/10000, Affinity BioReagents, Golden, CO, United States), HCV nonstructural protein 3 (clone1847, dilution: 1/2000, Viro-Stat, Portland, ME, United States) were used to analyze HCV expression, mouse monoclonal antibodies (mAbs) TGF- β 1 (ab 190503, dilution: 1/2000, Abcam, United Kingdom), HSP-47 (M16.10A1, dilution: 1/1000, Enzo life sciences, France), Collagen I alpha 1 (NB600-450, dilution: 1/2000, Novus Biologicals, CO, United States), MMP-9 (ab119906, dilution: 1/2000, Abcam, United Kingdom), VEGF (ab69479, dilution: 1/2000, Abcam, United Kingdom), β -actin (A5316, dilution: 1/5000 Sigma-Aldrich, Merck, Germany), and rabbit polyclonal antibodies (rAbs) to MMP-2 (ab92536, dilution: 1/1000, Abcam, United Kingdom), alpha-smooth muscle actin [α -SMA (ab 5694, dilution: 1/2000, Abcam, United Kingdom)] allowing fibrosis analysis, were used as primary antibodies. Horseradish peroxidase-conjugated anti-mouse IgG and horseradish peroxidase-conjugated anti-rabbit IgG (Amersham, GeHealthCare Life Sciences, United Kingdom) secondary antibodies, taken 1:50000, were used as secondary antibodies. The reactions were developed using enhanced chemiluminescence detection reagents (ECL Advance kit, Amersham, GeHealthCare Life Sciences, United Kingdom), followed by exposure to X-OMAT film (Amersham, GeHealthCare Life Sciences, United Kingdom).

Histology and immunohistochemistry

Liver sections (7 μ m) were stained with Goldner's trichrome (Electron Microscopy Sciences, United States) or picosirius red (Abcam, United Kingdom), performed

standard protocols for collagen/connective tissue labelling using two slices per human liver sample and two different human liver samples per group. The images were taken with the EVOS XL Core Imaging System (Invitrogen, Thermo Fisher Scientific, France). The average integrated optical density (OD) of collagen deposition was calculated using the image quantification standard software, ImageJ2^[20,21] or inform V2.1 (Perkin Elmer, MA, United States) used routinely in the histology (HISTIM) facilities (Cochin Institute, Paris, France). Immunostaining for TGF- β 1 (mAbs, ab92486, Abcam, United Kingdom), MMP-9 (mAbs, ab119906, Abcam, United Kingdom), Ki67 (rAbs, ab15580, Abcam, United Kingdom), and alpha-SMA (rAbs, ab5694, Abcam, United Kingdom) was performed after paraffin removal in xylene, rehydration in EtOH and then distilled water following the manufacturer's instructions. Unmasking of the antigenic sites was performed at 120 °C in 10 mmol/L citrate buffer, pH 6.0. A solution of 3% H₂O₂ was used to eliminate endogenous peroxidases. The sections were washed 3 times for 5 min. in TBS-Triton 0.1% solution. After incubation in a blocking solution (TBS-Triton 0.1%-3% dry milk) for 1 h at room temperature, they were incubated with the primary antibodies. All primary antibodies were diluted at 1/50 in the blocking solution. After incubation for 2 h at room temperature, the sections were washed 3 times and incubated with secondary antibodies. The nuclei were stained with DAPI. All sections were counterstained with hematoxylin for tissue quality control. Control sections incubated with non-immune serum were used as negative controls.

TGF- β 1 and Triglyceride quantification

TGF- β 1 and triglyceride quantification were performed according to the manufacturer's instructions (TGF- β 1 Quantikine ELISA, RD Systems, United States; Triglyceride assays Kit-Quantification, ab65336, Abcam, United Kingdom). For TGF- β 1, cellular lysates and culture supernatants were first treated with acid to lower the pH to 2.0, which denatures the latency-associated peptide and allows the detection of active TGF- β 1. The supernatant was then brought back to neutral pH before the ELISA assays.

ATP production quantification and LDH assays

To check viability, the percentages of ATP was assessed at each point of the kinetics studies during the liver slices culture and determined by ELISA assays (CellTiter-Glo® 2.0 Assay, Promega, France)^[19]. The viability of liver slices and the potential cytotoxicity^[20] (cytoTox 96R Non-Radioactive Cytotoxicity Assay, Promega, France) induced by Ethanol, or Palmitate, or drugs treatments was estimated as described previously^[11,12], in accordance with the manufacturers' protocols.

Drugs inhibition of fibrosis markers expression and cytotoxicity assays

Human LS were infected or not with the HCVcc Con1/C3 supernatant as previously described^[11,12]. On day 0 of the culture, treatment either with (240 ng/Liver slice) UCDA or (170 ng/Liver slice) Toco or both (the recommended standard of care) or 0.5% of dimethyl sulfoxide (Sigma Aldrich, Merck, Germany) as a control, were added to HCV-infected or non-infected LS culture medium every day to day 20. TGF- β 1 and Procol1A1 RNA expression were measured at different time points of the kinetic studies. All experiments were performed in triplicate.

Statistical analysis

Liver specimens from 20 individuals were examined. During the kinetic studies, the quantification of gene expression was determined in relation to the percentage of liver slice viability. The results were obtained from the mean of the three liver slices, on the different days of the kinetic studies. Statistical tests were performed using GraphPad Prism 8.0 software (GraphPad Software, La Jolla, CA, United States). Values are expressed as means \pm standard errors of the mean. The data were compared using either the unpaired two-tailed Student's *t*-test or the two-way ANOVA test with multiple comparisons for a given day as compared to the standard LS. A *P* value of 0.05 or less was considered significant.

RESULTS

Maintenance of phenotypic characteristics and viability of three dimensional human non-fibrotic (stages F0-F1) and fibrotic (stages F2-F4) LS cultures for 21 days of cultivation

The viability of human LS cultures during prolonged studies was and is a crucial factor. Liver slices viability (percentage of ATP production) and tissue morphology were assessed daily, until day 21. The architecture of the liver slices was normal (Figure 2A) and human liver slices (HLS) expressed the Ki67 protein, a proliferation marker (Figure 2B). Human LS cultures maintained their differentiation status throughout the entire study period, as previously described (Figure 2A-C)^[10,12]. Indeed, LS status was confirmed by analysing various parameters and biomarkers, in particular, albumin content, hepatocyte nuclear factors HNF-1 β , HNF-4 α , CYP2E1, and CYP3A4 (Figure 2D)^[10-12,22-24]. A comparison of the expression of hepatocyte-specific genes in F0-F1 non-infected liver slices and Huh-7.5.1 cells showed increased expression in F0-F1 non-infected liver slices on day 21 compared to that in Huh-7.5.1 cells, either at an exponential growth phase or at the confluence (data not shown). CYP3A4 expression was undetected in Huh-7.5.1 cells whatever the growth stage^[25]. Albumin and urea secretion increased throughout, indicating that liver slices had retained normal physiological and biochemical parameters (Figure 2E-F)^[11,12]. As previously reported^[11], the cell viability and expression of hepatocyte-specific genes were also evaluated post- HCVcc^[11]. Results were similar to those in uninfected liver slices, indicating that there was no evident cytopathic effect (Figure 3A-C).

The viability of non-fibrotic (F0-F1) and fibrotic (F2-F4) LS cultures and resistance to EtOH and palmitate treatments were tested during the 21 d follow-up studies by evaluating of the rate of ATP production in the liver slices (Figure 4A, C-E and G)^[22], and by quantification of LDH release from liver slices (Figure 4B-F)^[23]. On day 21, the F0-F1 and F2-F4 non-infected liver slices had a viability rate of 75% and 50%, respectively (Figure 4A). Following treatment with 25 mmol/L of EtOH, ATP synthesis in F0-F1 infected liver slices was reduced by 55% on day 21 (Figure 4D), and tissue viability decreased by nearly 25% compared to untreated F0-F1 non-infected/infected liver slice cultures (Figure 4C and D). However, the addition of EtOH (25 mmol/L) did not change LDH release in F0-F1 and F4 non-infected LS cultures (Figure 4F). Treatment with palmitate (500 μ mol/L) did not reduce significantly the viability rate of F0-F1 non-infected and infected LS cultures, compared to untreated and non-infected LS cultures (55% and 65%, respectively) (Figure 4G). There was no significant difference in LDH release from F0-F1, F2-F3, and F4 non-infected and infected LS cultures after treatment with the combination of UCDA and alfa-Toco (Figure 4H and I). Results of ATP production in F0-F1, F2-F3, and F4 non-infected and infected LS cultures after treatment with the combination of UCDA and alfa-Toco were significantly positive (Figure 4J-K) with increased ATP production in Fibrotic treated liver slices. These results, showing no significant changes in viability (with increasing levels of albumin, urea secretion as well as ATP production throughout the experiments) or morphology (Ki67 marker expression), confirm that the non-fibrotic (F0-F1) and fibrotic (F2-F4) LS cultures can survive for 21 days, and that the 3D LS cultures tolerated the different treatments (Figure 4H-K). Thus, LS cultures from selected donors can be used in extended research.

Evaluation of the expression of fibrogenesis liver biomarkers in 3D LS cultures from non-fibrotic (F0-F1) and fibrotic (F2-F4) livers

Activation or down-regulation of certain biomarkers reflects the process of the transition of the non-fibrotic liver to the fibrotic liver designated as the molecular fibrogenesis. We measured the expression of seven fibrosis biomarkers (TGF- β 1, Hsp47, α -SMA, Procol1A1, MMP-2, MMP-9, and VEGF)^[1,26] by RT-qPCR to analyse both non-fibrotic (F0-F1) and fibrotic (F2-F3, F4) stages of the liver in human LS cultures.

Induction of fibrogenesis by three exogenous factors: HCV, EtOH, and fatty acids (palmitate) in non-fibrotic (F0-F1) and fibrotic (F2-F4) LS cultures

HCV efficiently replication in LS cultures: A model of the viral liver disease: Robust replication of HCVcc and production of infectious viral particles were detected up to day 21 in human F0-F1 LS (Figure 5). Intracellular replication of the viral genome was assessed by a strand-specific RT-qPCR, as previously described^[11]. The HCV RNA negative strand, proof of HCV genome replication, could be detected as early day 1




Figure 2 Maintenance of phenotypic characteristics of human non-fibrotic (F0-F1), and fibrotic (F2-F3, F4) liver slices during the culture, demonstrated by histochemistry, real-time reverse transcription-quantitative polymerase chain reaction and biochemical assays. A: Light microscopy of human liver tissue 7 μ m-thick section stained with hematoxylin and eosin showing non-fibrotic (F2-F3) liver lobular architecture on day 15, magnification $\times 20$. Scale bars 100 μ m; B: Representative human liver tissue 7 μ m-thick sections from fibrotic (F2-F3) liver patient showing immunostaining for Ki67, a proliferation marker, on day 15, magnification $\times 40$, Scale bars, 20 μ m; C: Representative human liver tissue 7 μ m-thick sections from fibrotic (F2-F3) liver patient showing immunostaining with isotype as negative control, on day 15, magnification $\times 40$, Scale bars, 20 μ m; D: Hepatocyte-specific gene mRNA expression (relative expression/mg tissue) during the 21 days follow up studies. Maintenance of hepatocyte-specific gene expression patterns in human non-fibrotic (F0-F1) non-infected liver slices during culture. The real-time reverse transcription-quantitative polymerase chain reaction analyses were performed from five independent human non-fibrotic (F0-F1) livers using slices in triplicate from each liver. All liver-specific gene expression values were normalized to 18S RNA as an internal standard and expressed relative to the zero-time point. Values are expressed as mean \pm standard errors. The results were compared using the two-paired Student's *t*-test: Albumin: $^aP < 0.0001$; CYP2E1: $^aP < 0.001$; CYP3A4: $^bP < 0.0003$; HNF1- β : $^bP < 0.01$; HNF4- α : $^cP < 0.008$; E and F: Biochemical functional assays; E: Albumin production (pg \times 100/mg tissue/h) during the 21 days follow up studies; and F: Urea production (pg/mg tissue/hour) during the 21 days follow up studies. Studies were done in triplicate and repeated twice for each liver sample. Values are expressed as means \pm standard errors ($n = 5$). The results were compared using the two-paired Student's *t*-test: albumin production ($^dP < 0.02$), urea production ($^eP < 0.001$).

post-infection, and the intracellular levels of both negative and positive strands increased significantly during LS culture. These results confirmed active viral replication in LS cultures (Figure 5A). The HCV expression level was significantly increased in the LS culture on day 5 post-infection (Figure 5A). HCV protein expression was confirmed by Western blotting. Detection of core and nonstructural protein 3 proteins confirmed effective intracellular processing of the viral protein precursor^[11] (Figure 5B and C).

The virus titer was estimated in LS culture supernatants using a classic titration assay on Huh-7.5.1 cells to determine whether progeny virions released from the infected LS could replicate^[11]. Infectivity increased during the culture and reached a peak of up to 1.7×10^5 ffu/mL respectively, by day 21 post-infection (Figure 5D). To further confirm that the new progeny virus produced by the human LS called the primary-culture-derived virus was indeed infectious, naive human LS were infected *de novo* with primary-culture-derived virus Con1/C3 at MOI = 0.1. A *de novo* productive infection of LS was obtained with higher infectivity titers on day 21, genotype1b (180000 ffu/mL) (Figure 5E). Thus, HCV RNA replication, the expression of viral proteins, and the production of highly infectious particles were demonstrated.

HCVcc infection of non-fibrotic (F0-F1) LS activated the expression of the main pro-fibrogenic markers. During follow-up studies, in non-fibrotic (F0-F1) LS cultures (Figure 6), RNA, and protein expression of TGF- β 1 (Figure 6A-C), α -SMA, Hsp47, Procol1A1, (Figure 6D-F) had increased significantly in non-infected and infected LS on day 21. A marked 2.6 to 3.6 fold increase of α -SMA, Hsp47, Procol1A1 RNA expression was observed in non-fibrotic (F0-F1) HCV infected LS cultures, compared to non-infected LS cultures on day 21. MMP-2 RNA expression was also significantly increased after HCV infection in non-fibrotic F0F1 LS, (Figure 6G). On the contrary,











Figure 3 Maintenance of phenotypic characteristics of human non-fibrotic (F0-F1) hepatitis C virus-infected liver slices during the culture, demonstrated by real-time reverse transcription-quantitative polymerase chain reaction and biochemical assays. A: Hepatocyte-specific gene mRNA expression (relative expression/mg tissue) during the 21 days follow up studies. Maintenance of hepatocyte-specific gene expression patterns in human non-fibrotic (F0-F1) hepatitis C virus (HCV) infected liver slices during the culture. The real-time reverse transcription-quantitative polymerase chain reaction analyses were performed from five independent human non-fibrotic (F0-F1) liver samples, using HCV- infected slices in triplicate from each liver. Liver slices were infected with HCVcc, on day 0, at MOI = 0.1. All liver-specific gene expression values were normalized to 18S RNA as an internal standard and expressed in relation to the zero-time point. Values are expressed as mean \pm standard errors. The results were compared using the two-paired Student's *t*-test: Albumin, ^a*P* < 0.0001; CYP2E1: ^a*P* < 0.0001; CYP3A4: ^a*P* < 0.0001; HNF1- β : ^a*P* < 0.0001; HNF4- α : ^a*P* < 0.0001; B and C: Biochemical functional assays: B: Albumin production (pg x 100/mg tissue/ hour) during the 21d- follow up studies (days). C: Urea production (pg/mg tissue/hour during the 21d- follow up studies (days) by human F0-F1 cultured HCV-infected liver slices (*n* = 5). The assays were performed as previously described^[11,12]. Studies were performed in triplicate and repeated twice for each liver sample. Values are expressed as means \pm standard errors (*n* = 5). The results were compared using the two-paired Student's *t*-test: Albumin production: ^a*P* < 0.001; urea production: ^a*P* < 0.0001.

there was no significant difference in MMP-9 RNA expression between F0-F1 non-infected and infected liver slices (Figure 6H). VEGF RNA expression increased irregularly up to day 21 and seemed to be influenced by HCV infection until day 5 compared to non-infected LS (Figure 6I). The triglyceride production increased in both F0-F1 non-infected and infected LS cultures (Figure 6J) with no significant difference between them.

Expression of fibrosis biomarkers was higher in fibrotic LS culture (stages F2-F3 and F4), than in non-fibrotic LS cultures, with a significant 4 to 8 fold increase compared to controls (day 1) (Figure 7). This mainly concerned TGF- β 1 (Figure 7A), Procol1A1 (Figure 7C), α -SMA (Figure 7D), Hsp47 (Figure 7E) as well as an increased triglyceride production in fibrotic LS (approximately 3.2 fold) (Figure 7B). After day 10, RNA expression increased with the progression of fibrosis. MMP-2 RNA expression (Figure 7F), as well as MMP-9 and VEGF expression (Figure 7G and H), did not differ between fibrosis stages F2-F3 and F4. It is interesting to note that HCV infection significantly increased TGF- β 1, Hsp47, α -SMA, Procl1A1, MMP-2, MMP-9, VEGF expression as well as triglyceride production in fibrotic (F2-F3, F4) infected LS cultures. A significant 2 to 4 fold increase in fibrosis biomarkers was observed on day 21 in F2-F3 and F4 HCV infected LS compared to F2-F3, F4 non-infected LS. Thus, the TGF- β 1 (Figure 6A-C), α -SMA, Hsp47, Procl1A1, MMP-2, MMP-9, VEGF expression increased in non-infected and infected LS cultures with a greater increase in infected LS cultures than in controls. On day 21, a significant 2 to 13 fold increase in fibrosis biomarkers was observed in F2-F3, F4 infected LS cultures compared to F2-F3, F4 non-






Figure 4 Viability of human non-fibrotic (F0-F1), and fibrotic (F2-F3, F4) non-infected or hepatitis C virus-infected liver slices during the different kinetic studies, with no treatment cytotoxicity as shown by ATP and LDH dosages. A: Percentage of ATP synthesis/total protein in non-infected (NINF) liver slice (LS) with F0-F1 to F4 stage fibrosis during the 21 days-follow up kinetics; B: The percentage of LDH release/control in NINF LS with a F0-F1 to F4 stage fibrosis during the 21d-follow up kinetics (d: days); C and D: The percentage of ATP synthesis /total protein in F0-F1 NINF and hepatitis C virus (HCV)-infected (INF) LS treated with 1 mmol/L, 5 mmol/L and 25 mmol/L of EtOH during the 21d-follow up kinetics; E: The percentage of ATP synthesis / total protein in the presence of 25 mmol/L of EtOH on F0-F1 NINF and INF LS during the 21d-follow up kinetics; F: LDH release (% of control) in F0-F1 non-infected LS cultures treated or non-treated with 25 mmol/L of EtOH compared to F4 non-infected treated or non-treated with 25 mmol/L of EtOH during the 21d-follow up kinetics. Values are expressed as means \pm standard errors (SEMs), ($n = 5$). ^a $P < 0.0001$ time factor; ^b $P < 0.01$ fibrosis stage; ^c $P < 0.05$ fibrosis stage; ^d $P < 0.05$ alcohol factor; ^e $P < 0.01$ subject vs control (non-treated) (two-way ANOVA test). There is no significant toxic effect of EtOH (25 mmol/L) on F0-F1 NINF and INF LS and F2-F3, F4 NINF LS; G: The percentage of ATP synthesis/total protein during the 21-follow up kinetics showing the viability of F0-F1 NINF or INF LS cultures with or without the presence of palmitate (500 μ mol/L); H and I: Absence of drug cytotoxicity (LDH release, (% of control)) on the viability of human F0-F4 LS NINF or infected (INF) by HCVcc Con1/C3 during the treatment with either UCDA (UA) or Toco or both for 21 days. It is important to note that under 150%, there is no cytotoxic effect of the drugs on LS viability. Values are expressed as means \pm SEMs, ($n = 5$); J and K: The percentage of ATP synthesis / total protein during the 21 days follow up kinetics, in F0-F1 to F4 NINF or infected (INF) LS with combined treatment [Toco + UCDA (UA)]. Values are expressed as means \pm SEMs, ($n = 5$); Levels of significance are as follows between: Subject vs control, ^k $P < 0.0001$; ^l $P < 0.001$; ⁱ $P < 0.01$; ^h $P < 0.05$) (two-way ANOVA test).

infected LS cultures. Triglyceride production increased in both non-infected and infected LS cultures, independent from the stage of fibrosis. After 21 d of the culture, the amount of triglyceride in the supernatant of F2-F3 and F4 LS cultures increased by 1.36 and 2.7 folds, respectively (Figure 7B). Increased expression of the TGF- β 1, α -SMA, Procol1A1, MMP-2, MMP-9, and VEGF in F2-F3 LS cultures throughout the 21-d of follow-up was confirmed by Western blotting (Figure 7I and J). On day 10, immunohistochemistry showed that TGF- β 1, α -SMA and MMP-9 expression (Figure 7K) was increased by about 20% in F2-F3 LS compared to day 0.





Figure 5 Efficient replication of hepatitis C virus RNA, and hepatitis C virus core and NS3 proteins expression in human F0-F1 liver slice culture as shown by real-time reverse transcription-quantitative polymerase chain reaction and western blotting analysis. A: Quantification of intracellular levels of positive- and negative-strand hepatitis C virus (HCV) RNA (log₁₀ copies/μg total RNA/mg tissue) in primary human F0-F1 HCVcc Con1/C3 -infected liver slice (LS) by specific- strand real-time reverse transcription-quantitative polymerase chain reaction on day 5, day 10, day 15 and day 21 post-infection. Values are expressed as mean ± SEMs. All results were compared using the two-paired Student *t*-test, time factor: Positive strand: ^q*P* < 0.01; negative strand: ^q*P* < 0.04, (*n* = 3). Detection of the negative strand of HCV RNA evidences active replication as well as an increase over time of both positive and negative strands of HCV RNA; B: Western blotting analysis of human F0-F1 HCVcc Con-1/C3 -infected LS lysates with mAbs against HCV NS3 or core proteins on day 5, day 10, day 15, and day 21, post-infection (MOI = 0.1) was performed and analyzed (*n* = 3). Lysates of naïve human F0-F1 LS lysates were run in parallel to serve as a negative controls (NI). β-actin was used as a loading control; C: Normalization of Core and NS3 protein expression compared to β-actin expression (Normalized protein / β-actin) during the 21 days follow-up kinetics using the image quantification standard software, ImageJ2^[21]. The position of molecular-weight markers is indicated in kDa. Values are expressed as means ± SEMs (*n* = 3): Core ^r*P* < 0.002; NS3 ^s*P* < 0.02 (two-paired Student *t*-test); D: Production of HCV infectious particles (genotype 1b) in primary adult human F0-F1 LS: Infectivity titers [*i.e.*, infectivity (ffu/mL/mg tissue)] of culture supernatants from human F0-F1 LS infected by the Con1/C3 virus during the 21 days follow up kinetics. The curve represents the average of three independent infections from 3 different donors. Each kinetic study was performed in triplicate. Values are expressed as means ± SEMs. Results were compared using the two-paired Student *t*-test: ^s*P* < 0.02; and E: Infectivity titers [*i.e.*, infectivity (ffu/mL/mg tissue)] of culture supernatants of naive F0-F1 LS infected with supernatants from human F0- F1 HCV-infected LS culture (HCVpc) during the 21 days follow up kinetics. The infection of naive F0-F1 LS with supernatants from human F0-F1 HCV-infected LS culture (HCVpc) clearly indicates the infectivity of extracellular viral particles, which are produced by HCVcc Con1/ C3 (genotype 1b) infection. Values are expressed as means ± SEMs (*n* = 3). Levels of significance: ^e*P* < 0.001 (two-paired Student *t*-test).

Exposition of LS cultures to ethanol: A model of the alcoholic liver disease: The effect of EtOH exposure on LS cultures was estimated using non-fibrotic (F0-F1) HCV infected or non-infected LS cultures (Figure 8A-F and Figure 9) and fibrotic (F2-F4) HCV infected or non-infected LS cultures (Figure 8G-L) and Figure 10A-L). One mmol/L, 5 mmol/L or 25 mmol/L of EtOH was added to F0-F1 HCV infected, or non-infected LS cultures (Figure 8A-F). Only the highest concentration of EtOH was studied in fibrotic (F2-F3 and F4) non-infected or HCV-infected LS cultures, (Figure 8G-L and Figure 10A-L) respectively. During the follow-up studies (Figure 8A-F), EtOH enhanced the RNA expression of fibrosis markers in a dose-dependent manner in F0-














Figure 6 Real-time reverse transcription-quantitative polymerase chain reaction analysis evidencing the significant increase of fibrosis markers expression at the transcriptional level in human F0-F1 non-infected or hepatitis C virus infected liver slice during the kinetics. A: TGF- β 1 expression at mRNA level (relative RNA expression / mg tissue) during 21 days follow up kinetics; B: TGF- β 1 expression at intracellular protein level (pg/mg protein) during 21 days follow up kinetics; C: TGF- β 1 expression at extracellular secretion level (pg/mL) during 21 days follow up kinetics; D-F: mRNA expression (relative RNA expression / mg tissue) of (D) α -SMA, HSP47 (E) and ProCOL1A1 (F) during 21 days follow up kinetics; G and H: MMP-2 and MMP-9 mRNA expression (relative RNA expression / mg tissue) during 21 days follow up kinetics; I: VEGF mRNA expression (relative RNA expression/mg tissue) during 21 days follow up kinetics; J: Triglyceride production (μ g/mg protein) raised during the 21 days follow up kinetics. All data are presented considering the percentage of viable liver slices in culture. Data are expressed as means \pm SD ($n = 5$), subject vs control, ^h $P < 0.05$; ⁱ $P < 0.01$; ^j $P < 0.001$; ^k $P < 0.0001$, (two-way ANOVA test).

F1 LS cultures. Increased expression of TGF- β 1, Procol1A1 RNA was further detected in F0-F1 infected LS (Figure 8B, D and F, Figure 9B, Figure 10B), compared to non-infected LS (Figure 8A, C and E, Figure 9A, Figure 10A). Similar results were found in fibrotic F2-F4 LS (Figure 8G-L, Figure 10A-L). Interestingly, there was no significant increase in Procol1A1 or α -SMA RNA expression in F0-F1 non-infected LS except on day 21 when 25 mmol/L of EtOH was added to the culture (Figure 8E and Figure 9C, respectively). However, a significant dose-dependent increase of the Procol1A1 and α -SMA RNA expression occurred whatever the dose of EtOH added to F0-F1 infected LS cultures (Figure 8F, Figure 9D). There was a dose-dependent increase in the RNA expression of the other fibrosis markers such as α -SMA (Figure 9C and D; Figure 10E and F), and HSP47 (Figure 9E and F, Figure 10C and D) with the addition of EtOH in F0-F1 to F4 infected LS which was less marked in F0-F1 to F4 non-infected LS. Analysis of F0-F1 to F4 HCV non-infected or infected LS showed a significant dose-dependent increase in MMP-2, MMP-9, and VEGF expressions in response to EtOH (Figure 10G-L). Masson's trichrome staining showed a significant increase in collagen fibers (%) between day 1 (1.242% of collagen) and day 6 (2.076% of collagen) in F0-F1 HCV infected LS treated with 5 mmol/L of EtOH (Figure 8M) but not in F0-F1 non-infected LS with the same treatment (Figure 8N). Picro Sirius red staining confirmed the significant increase in collagen fibers (%) between day 1 (0.55% of collagen) and day 6 (1.53% of collagen) in F0-F1 HCV infected LS treated with 5 mmol/L of EtOH compared to non-treated LS (data not shown).

Exposition of LS cultures to palmitate: a model of NASH. To imitate NASH, non-fibrotic (F0-F1) LS cultures infected (or not infected) with HCV were exposed to 500 μ mol/L of palmitate (Figure 11). More marked triglyceride synthesis was noted in F0-F1 palmitate treated HCV-infected LS cultures, than in F0-F1 untreated non-infected LS cultures (Figure 11A). The F0-F1 infected LS cultures treated with palmitate demonstrated more marked expression of the fibrotic markers such as TGF- β 1 (Figure 11B), intracellular expression of TGF- β 1 (Figure 11C), and secretion of the extracellular TGF- β 1 (Figure 11D). A similar increase was observed with Procol1A1, α -SMA, and HSP47 (Figure 11E-G) on day 21. The expression of markers (RNA) involved in liver fibrolysis, (MMP-2, -9), and VEGF increased significantly in both F0-F1 non-infected LS cultures treated or not with palmitate (Figure 12A). But, the treatment of F0-F1 non-infected LS cultures with palmitate showed a greater significant increase of the expression of MMP-2, -9, and VEGF compared to those of F0-F1 untreated non-infected LS cultures. The treatment of the F0-F1 infected LS cultures with palmitate, increased significantly VEGF, MMP-2, and MMP-9 from day 10, 15, and day 21 respectively (Figure 12B). Fibrotic marker expression increased both in F0-F1 LS cultures HCV infected or non-infected treated with palmitate but with a greater increase in F0-F1 HCV infected LS treated with palmitate.














Figure 7 Real-time reverse transcription-quantitative polymerase chain reaction analyses of RNA expression of liver fibrosis markers (TGF-β1, Procol1A1, α-SMA, HSP47, MMP-2, MMP-9, VEGF), and triglyceride production in non-infected or hepatitis C virus infected liver slice cultures from fibrotic liver (F2-F3, F4) showing a significant increase during the kinetics. A: TGF-β1 mRNA Expression (relative RNA expression/mg tissue) during 21 days follow up kinetics; B: Triglyceride production (μg/mg protein); C–E: Procol1A1, α-SMA, HSP47 mRNA expression (relative RNA expression / mg tissue) during 21 days follow up kinetics; F–H: MMP-2, MMP-9 and VEGF mRNA expression (relative RNA expression/mg tissue) during 21 days follow up kinetics. Data are expressed as mean ± SD (F2-F3 liver samples, $n = 2$, F4 liver samples, $n = 2$). ^b $P < 0.01$ fibrosis stage factor; ^m $P < 0.001$ Infection factor; ^l $P < 0.0001$ infection factor; (two-way ANOVA test); I: TGF-β1, HSP-47, Collagen I alpha 1, MMP-9, MMP-2, α-SMA, VEGF proteins expression in F2-F3 liver slice performed in western blotting and normalized. Positions of molecular-weight markers are indicated in kDa; J: Normalization of the proteins expression compared to β-actin expression (Normalized protein/β-actin) during the 21 days follow-up kinetics using the image quantification standard software, ImageJ2; and K: Representative human liver tissue 7 μm-thick sections from F2-F3 liver patient showing immunohistochemistry staining for fibrosis markers, TGF-β1 (a), α-SMA (b), MMP-9 (c) on day 10, magnification 20×, Scale bars, 100 μm; 40×, Scale bars 50 μm; 10×, Scale bars 100 μm, respectively. (d-f) isotypes controls staining, magnification 10×, Scale bars, 100 μm; 40×, Scale bars 20 μm; 10×, Scale bars 200 μm, respectively.

LS treatment with a combination of the “hepatoprotective” UCDA and anti-fibrotic α-Toco drugs significantly reducing the expression of the main fibrosis markers TGF-β1, Procollagen1A1, and triglyceride production

To validate the LS culture as a model for drug screening, the “hepatoprotective” (UCDA) and “anti-fibrotic (Toco) drugs were tested on non-fibrotic (F0-F1), or fibrotic (F2-F3, F4) LS cultures, infected or non-infected with HCV. UCDA and Toco were dosed according to the standard of care in humans (Figure 13). On day 0, LS cultures were infected with HCVcc Con1/C3 (MOI = 0.1) and treated either with daily doses of UCDA and /or with Toco for up to day 21.

During the 21-days long follow-up studies of F0-F1, F2-F3, and F4, LS cultures, a significant, 25% to 50%, reduction in TGF-β1 RNA expression was only identified in F4 LS cultures treated with Toco, from day 5 and day 10 of the culture in non-infected and HCV infected LS cultures, respectively (Figure 13A and B). Treatment with UCDA did not induce a significant reduction in TGF-β1 RNA expression in any non-infected F0-F4 LS cultures (Figure 13C). Interestingly, from day 15, at least a two-fold reduction






Figure 8 Significant increased expression of TGF-β1 and Procol1A1 mRNA with ethanol (1 mmol/L, 5 mmol/L, 25 mmol/L) treatment of non-infected or hepatitis C virus INF liver slice cultures from non-fibrotic (F0-F1) and ethanol (25 mmol/L) treatment of non-infected or

hepatitis C virus infected liver slice cultures from fibrotic (F2-F3, F4) liver samples as shown by real-time reverse transcription-quantitative polymerase chain reaction and ELISA and histochemistry. A and B: TGF- β 1 mRNA expression (relative RNA expression / mg tissue) during 21 days follow up kinetics with ethanol (EtOH) (1 mmol/L, 5 mmol/L, 25 mmol/L) treatment in non-infected (NINF) or hepatitis C virus (HCV) INF liver slice (LS) cultures from non-fibrotic (F0-F1); C and D: Extracellular TGF- β 1 protein expression (pg/mL) during 21 days follow up kinetics, with EtOH (1 mmol/L, 5 mmol/L, 25 mmol/L) treatment of NINF or HCV INF LS cultures from non-fibrotic (F0-F1); E and F: Procol1A1 mRNA expression (relative RNA expression/mg tissue) during 21 days follow up kinetic, with EtOH (1 mmol/L, 5 mmol/L, 25 mmol/L) treatment of NINF or HCV INF LS cultures from non-fibrotic (F0-F1); G and H: TGF- β 1 mRNA expression (relative RNA expression/mg tissue) during 21 days follow up kinetics, in fibrotic (F2-F3, F4) NINF and HCV INF LS treated with 25 mmol/L of EtOH compared to F0F1 NINF or HCV INF LS cultures in presence of the 25 mmol/L EtOH; I and J: Extracellular TGF- β 1 protein expression (pg/mL) during 21 days follow up kinetics, in fibrotic (F2-F3, F4) NINF and HCV INF LS after treatment with 25 mmol/L of EtOH compared to F0F1 NINF or HCV INF LS cultures in presence of 25 mmol/L EtOH; K and L: Relative Procol1A1 mRNA expression (relative RNA expression/mg tissue) during 21 days follow up kinetics, in fibrotic (F2-F3, F4) NINF and HCV INF LS treated with 25 mmol/L of EtOH compared to F0F1 NINF or HCV INF LS cultures in presence of 25 mmol/L EtOH. Data are expressed as means \pm SEM (F0-F1, $n = 5$; F2-F3, $n = 2$; F4, $n = 2$). ^k $P < 0.0001$ subject vs control (non-treated); ⁱ $P < 0.001$ subject vs control (non-treated); ^j $P < 0.01$ subject vs control (non-treated), ^h $P < 0.05$ subject vs control (non-treated) (two-way ANOVA test); M: Significant increase of collagen deposition (% of collagen deposition) in F0-F1 HCV INF LS treated with 5 mmol/L of EtOH (E5) on day 6 (D6) compared to day 1 (D1); N: No significant change of collagen deposition (% of collagen deposition) in F0-F1 non-infected (NINF) LS treated with 5 mmol/L of EtOH (E5) on day 6 (D6) compared to day 1 (D1). Data are expressed as means \pm SEM ($n = 8$). ⁱ $P < 0.01$ subject vs control (non-treated), (unpaired two-tailed Student's *t*-test). Magnification 20X, Scale bars 100 μ m.

in TGF- β 1 RNA expression, at least, F2-F3, and F4 infected LS cultures was observed (Figure 13D). There was no change in TGF- β 1 RNA expression in non-infected LS treated with both UCDA and Toco, whatever the stage of disease (Figure 13E). TGF- β 1 RNA expression in F2-F3 and F4 infected LS cultures on days 5 and 15 was reduced by nearly two fold. On day 21, TGF- β 1 RNA expression in F4 LS cultures were reduced 2.5 fold (Figure 13F). During the 21-days follow-up studies of infected and non-infected F0-F1, F2-F3, and F4 LS cultures treated with both UCDA and Toco, procollagen1A1 expression was significantly reduced in non-infected and infected F0F1- F4 LS cultures compared to untreated cultures from day 15 (Figure 13G and H). In particular, the significant reduction of procollagen1A1 RNA expression (around two-fold) in treated F2-F3 infected LS cultures was observed from day 10 and from day 15 for treated F4 infected LS cultures. Triglyceride production in HCV non-infected and infected LS from F0-F1, F2-F3 and F4 LS cultures was significantly reduced by the combination treatment from day 10 in F4 HCV non-infected LS cultures (Figure 13I) and from day 1 in F4 HCV infected LS cultures (Figure 13J).

DISCUSSION

For the first time, different stages of human liver fibrogenesis were investigated *ex vivo* and for a relatively long period. Indeed, liver tissue slices remained viable for at least 21 days, as shown by the secretion of albumin and urea, the percentage of ATP production and LDH release observed during the kinetic experiment. However, the secretion of albumin and urea was lower than that in micropatterned hepatocyte cocultures models^[27]. Both fibrotic (stages F2-F4) and non-fibrotic (stages F0-F1) liver samples remained viable *ex vivo* for this period. Twenty one-day follow-up studies of LS cultures significantly improved the investigation of fibrogenesis in general, and fibrotic biomarkers, in particular. We obtained RT-qPCR analyses of the biomarkers (TGF- β 1, procol1A1, MMP-2, MMP-9, α -SMA, HSP47, and VEGF) involved in molecular fibrogenesis, and estimation of anti-fibrotic drugs potency, in both non-fibrotic (F0-F1) and fibrotic livers samples (F2-F3, F4). Additional evaluation of fibrotic biomarkers performed by ELISA, histology, and by Western blotting supported RT-qPCR data. With this *ex vivo* model, sustaining hepatocyte-specific gene expression for 21 days, we induced molecular fibrogenesis using HCV, EtOH, or palmitate, thus mimicking human viral, alcoholic, and NASH liver diseases.

The most important property of this LS model is cell viability for a relatively long period of time. The expression of diverse biomarkers of fibrosis was analyzed in the presence of HCV, EtOH or palmitate using non-fibrotic F0-F1 LS cultures. The markers of fibrogenesis and triglyceride production were found to be increased in both non-infected and infected LS cultures. The addition of either EtOH or palmitate significantly increased the expression of fibrotic biomarkers. Moreover, this increase was found to be greater in HCV infected than in non-infected LS with increased triglyceride production higher in infected LS. HCV infection seemed to enhance fibrosis marker expression in the presence of ethanol or palmitate.

It is important to mention, that TGF- β 1 expression, the principal marker of fibrogenesis, was higher in non-fibrotic (F0-F1) LS cultures cultivated in the presence












Figure 9 Significantly increase in TGF-β1 protein and RNA expression of α-SMA, and HSP47 in non-infected or hepatitis C virus-infected non-fibrotic (F0-F1) liver slice cultures treated with 1 mmol/L, 5 mmol/L and 25 mmol/L of ethanol was shown by enzyme-linked immunosorbent assay and real-time reverse transcription-quantitative polymerase chain reaction analyses. A and B: TGF-β1 intracellular protein expression (pg/mg protein) during 21 days follow up kinetics, in non-infected (A) and hepatitis C virus (HCV)-infected (B) F0-F1 liver slice (LS) cultures, treated with 1 mmol/L, 5 mmol/L, 25 mmol/L of ethanol (EtOH); C and D: Relative α-SMA RNA expression level (relative RNA expression/mg tissue) during 21 days follow up kinetics, in non-infected (C) and HCV-infected (D) F0-F1 LS cultures treated with 1 mmol/L, 5 mmol/L, 25 mmol/L of EtOH; E and F: Relative HSP47 RNA expression level expression (relative RNA expression / mg tissue) during 21 days follow up kinetics, in non-infected (E) and HCV-infected (F) F0-F1 LS cultures treated with 1 mmol/L, 5 mmol/L, 25 mmol/L of EtOH. All presented data take into account the viability of the liver slice cultures. Values are expressed as means ± SEMs ($n = 5$); Levels of significance: ^k $P < 0.0001$ subject vs control (non-treated); ^j $P < 0.001$ subject vs control (non-treated); ⁱ $P < 0.01$ subject vs control (non-treated), ^h $P < 0.05$ subject vs control (non-treated) (two-way ANOVA test).

of HCV and /or EtOH, or palmitate treatment. This effect was greater in fibrotic (F2-F4) LS cultures. Moreover, when fibrotic LS cultures were exposed to EtOH, a significant increase of α-SMA, HSP47, procol1A1 expression as well as the other markers involved in liver fibrolysis such as (MMP-2, -9) and VEGF was identified in both non-infected and infected liver slices.

The increased expression of fibrogenesis biomarkers was throughout the twenty-one days follow-up studies. RT-qPCR showed that the effect was more marked in LS cultures obtained from livers with advanced stages of fibrosis. This was confirmed for the following biomarkers: TGF-β1, α-SMA, HSP47, Procol1A1, MMP-2, -9, and VEGF. These results were further confirmed by Western blot analyses for TGF-β1, α-SMA, Col1A1, HSP47, MMP-2, -9, and VEGF. Thus, analyses of LS cultures revealed, that the






Figure 10 By real-time reverse transcription-quantitative polymerase chain reaction and enzyme-linked immunosorbent assay, significantly increase of TGF- β 1 protein and RNA expression of fibrosis biomarkers HSP47, α -SMA, MMP-2, MMP-9, VEGF increased in non-infected or hepatitis C virus-infected liver slice cultures from stages F0-F1 to stage F4 treated with 25 mmol/L of ethanol. A and B: TGF- β 1 intracellular protein expression (pg/mg protein) during the 21 days follow up kinetics, in F0-F1 to F4 non-infected (A) and hepatitis C virus (HCV)-infected (B) liver slice (LS), treated with 25 mmol/L of ethanol (EtOH); C and D: Relative HSP47 RNA expression (relative RNA expression/mg tissue) during the 21 days follow up kinetics, in F0-F1 to F4 non-infected (C) and HCV infected (D) LS treated with 25 mmol/L of EtOH; E and F: Relative α -SMA RNA expression (relative RNA expression / mg tissue) during the 21 days follow up kinetics, in F0-F1 to F4 non-infected (E) and HCV-infected (F) LS treated with 25 mmol/L of EtOH; G and H: Relative MMP-2 RNA expression (relative RNA expression / mg tissue) during the 21 days follow up kinetics, in F0-F1 to F4 non-infected (G) and HCV-infected (H) LS cultures treated with 25 mmol/L of EtOH; I and J: Relative MMP-9 RNA expression (relative RNA expression / mg tissue) during the 21 days follow up kinetics, in F0-F1 to F4 non-infected (I) and HCV-infected (J) LS treated with 25 mmol/L of EtOH; K and L: Relative VEGF RNA expression (relative RNA expression/mg tissue) during the 21 days follow up kinetics, in F0-F1 to F4 non-infected (K) and HCV-infected (L) LS cultures treated with 25 mmol/L of EtOH. Values are expressed as mean \pm SEMs (F0-F1: $n = 5$; F2-F3, $n = 2$; F4, $n = 2$). ^k $P < 0.0001$ subject vs control (F0-F1); ⁱ $P < 0.001$ subject vs control (F0-F1); ^j $P < 0.01$ subject vs control (F0-F1), ^h $P < 0.05$ subject vs control (F0-F1) (two-way ANOVA test).

progression of fibrosis is associated with an increase in the expression of certain biomarkers, in particular, α -SMA expression, and resembles a snowball effect, as shown by histochemistry results with a significant increase of collagen production in F0-F1 EtOH treated HCV infected LS on day 6 compared to day 1. As might be expected, a more marked fibrogenesis reaction was observed in fibrotic (F2-F3, F4) LS cultures, than that in non-fibrotic (F0-F1) LS cultures.

Thus, the LS model well responded to fibrotic inducers and, then, released a set of biomarkers that are usually detected during clinical studies in patients with fibrosis. In particular, this included TGF- β , α -SMA, Procollagen1A1, MMP-2, MMP-9, VEGF, the markers of liver fibrogenesis, whatever the origin of fibrosis. This study also showed the synergistic effect of liver comorbidities (virus, alcohol, and fat) on fibrogenesis and its consequences^[28,29]. Finally, the efficacy of hepatoprotective^[28] or anti-fibrotic drugs^[29] was suggested in the LS cultures model. Recently, Wu *et al*^[10] demonstrated that Human liver slices collected from resected livers could be maintained in *ex vivo* culture over a two-week period.

Several anti-fibrotic drugs are now in development^[27-29], following validation in animal models^[30], in particular, target inhibitors for the treatment of NASH-related fibrosis. This includes NGM282, an FGF19 analog that reduces steatosis, biliary acids injury, and lipotoxicity *via* 2 receptors, the MGL-3196, a THR- β 1 agonist that decreases LDL-cholesterol, triglyceride and fatty liver, thus lipotoxicity^[30,31]. Randomized controlled trials are known to take time and the results may be disappointing despite the encouraging results of the recent REGENERATE trial, in obeticholic acid^[32-36]. For example, Cenicriviroc, a dual CCR2/CCR5 antagonist with positive results in mice,




Figure 11 Significant increase of intracellular triglyceride production and RNA expression of fibrosis liver markers in non-fibrotic (F0-F1) hepatitis C virus INF liver slice cultures treated with palmitate (500 µmol/L) compared to non-infected and non-treated liver slice showed by enzyme-linked immunosorbent assay and real-time reverse transcription-quantitative polymerase chain reaction analyses, respectively. A: Triglyceride production (µg/mg protein) during the 21 days follow up kinetics: Non-significant production in hepatitis C virus (HCV) INF liver slice (LS) compared to non-infected (NINF) LS: (ns NINF vs INF); significant increase in HCV INF LS treated with palmitate compared to NINF; B: Significant increase of TGF-β1 mRNA expression (Relative RNA expression /mg tissue) during the 21 days follow up kinetics, in HCV INF LS compared to NINF LS and in HCV INF LS treated with palmitate compared to NINF; C and D: (C) Intracellular (pg/mg protein) and (D) extracellular (pg/mL) TGF-β1 protein production during the 21 days follow up kinetics, measured by enzyme-linked immunosorbent assay assays, in F0-F1 NINF and HCV INFLS cultures treated or non-treated with palmitate; Significant increase in HCV INF LS compared to NINF LS; Significant increase in HCV INF LS treated with palmitate compared to NINF; E-G: Intracellular mRNA expression (Relative RNA expression /mg tissue) of the Procol1A1 (E), α-SMA (F), HSP47 (G) during the 21 days follow up kinetics: Significant increase in HCV INF LS compared to NINF LS; Significant increase in HCV INF LS treated with palmitate compared to NINF LS. Data are expressed as mean± SEM (F0-F1, n = 5); ¹P < 0.0001 infection factor; ^mP < 0.001 infection factor; ⁿP < 0.0001 palmitate factor (two-way ANOVA test).

did not result in any significant reduction in NASH-related fibrosis after 2 years of studies^[37], and Selonsertib, an ASK1 inhibitor with putative anti-fibrotic properties, was recently withdrawn in the Stellar-3 and Stellar-4 Randomized controlled trials (Gilead, Press release, April 2019).

Although randomized clinical trials are the best way to prove the drug efficacy of a drug, there are several important limitations to this approach including the need for serial liver biopsies, suboptimal dosage schedules, or placebo double-blinded controls with a single drug. All of this can require about three years. With existing LS models, anti-fibrotic drug testing can be performed for 2-3 weeks (wk). Testing is possible for single drugs, drug combinations with similar or different agents, dose effects, stability in the liver, *etc...*

In the present study, we used our 3D LS *ex vivo* models to investigate the anti-fibrotic properties of two drugs, being tested in clinical trials. Ursodeoxycholic acid is indicated in the treatment of primary biliary cirrhosis and dissolve radiolucent gallstones in patients with a functioning gallbladder. Alpha-Tocopherol (Toco, vitamin E) is tested currently in patients with high cholesterol and NASH. A meta-analysis in a sub-group analysis of random clinical trials has shown that alpha-tocopherol has an anti-fibrotic effect compared to UCDA^[36,38]. These drugs were tested alone and in a combination with the LS model. The combined treatment is not tested during the first phase of the clinical trials. The half-life of UCDA is 3.5 to 5.8 days and that of Toco is 44.5 hours. Patients must be treated daily with UCDA for 2 to 3 months and for 96 wk with Toco to obtain some clinical effects. In the LS model, Toco treatment only reduced the TGF- β 1 expression in non-infected and infected LS with stage F4 after day 10. After day 15, UCDA reduced TGF- β 1 expression in stage F2 to F4 infected LS. It is interesting to note that with a combination of both drugs, TGF- β 1 and Procol1A1 expression was reduced significantly in LS. The level of TGF- β 1 decreased nearly 2 fold in F2-F3 infected LS on day 15 and 2.5 fold on day 21, in F4 infected LS cultures. A significant reduction in procol1A1 RNA expression was found with the combination treatment in F2-F3, and in F4 infected and non-infected LS cultures with a two-fold decrease on days 15 and 21. Obviously, to confirm the results, the other dosages and proportions of drugs (in combination) should be tested. In fact, this model showed a clear decrease in the main hepatic fibrogenesis biomarker TGF- β 1, in the presence of a combination of anti-fibrotic drugs (UCDA and Toco) in F2-F4 infected LS cultures with a significant decrease in both triglyceride production and Procol1A1 expression. Procol1A1 expression was significantly reduced in F2-F3, and F4 infected or non-infected LS cultures during combined treatment (UCDA and Toco). Thus, these data provide a proof of concept that this proposed 3D *ex vivo* model effectively allows a rapid evaluation of new anti-fibrotic drugs.

CONCLUSION

In summary, the 3D *ex vivo* LS model provides hepatocyte-specific gene expression for 21 days, and effectively reproduces liver fibrogenesis related to HCV infection, EtOH, or lipids exposure, thus, mimicking human viral, alcoholic, and NASH liver diseases. Our study is the proof of concept that this relatively easy model can be used to study human liver fibrogenesis of different origins and evaluate the potency of new anti-fibrotic therapies that are currently under development. In particular, this system might estimate unpredictable side effects when testing certain drug combinations.




Figure 12 Significant increase of matrix metalloproteinases -2, -9, and vascular endothelial growth factor RNA expression after treatment of F0-F1 non-infected and infected liver slice cultures with palmitate (500 μmol/L). Biomarker expression estimated by real-time reverse transcription-quantitative polymerase chain reaction. A: Matrix metalloproteinases (MMP)- 2, MMP-9 and vascular endothelial growth factor mRNA expression (relative expression /mg tissue) during the 21 days follow up kinetics, in F0-F1 non-infected liver slice (LS) cultures treated without or with palmitate (500 μmol/L); B: MMP- 2, MMP-9 and vascular endothelial growth factor mRNA expression (relative expression /mg tissue) during the 21 days follow up kinetics, in F0-F1 infected LS cultures treated without or with palmitate (500 μmol/L). Real-time reverse transcription-quantitative polymerase chain reaction experiments were performed with five independent human F0-F1 liver samples ($n = 5$). LS were obtained in triplicate for each liver sample, at each time point in the kinetic studies. Values are expressed as means \pm standard errors ($n = 5$). Levels of significance were as follows: $^jP < 0.001$ subject vs control (non-treated palmitate), (two-way ANOVA test).




Figure 13 During treatment with alpha-Tocopherol and ursodeoxycholic acid in combination, significant inhibition of the TGF-β1 mRNA

expression of fibrotic (F2-F3, F4) hepatitis C virus INF liver slice cultures from day 5 and significant reduction of Procol1A1 mRNA expression and the triglyceride production in F0 to F4 non-infected and hepatitis C virus INF liver slice cultures during the follow-up kinetics, as evidenced the real-time reverse transcription-quantitative polymerase chain reaction analysis and enzyme-linked immunosorbent assays, respectively. A and B: TGF- β 1 mRNA expression (relative TGF- β 1 expression /mg tissue) during the 21 days follow up kinetics, in α -Tocopherol (Toco) treated liver slice (LS); C and D: TGF- β 1 mRNA expression (relative TGF- β 1 expression /mg tissue) during the 21 days follow up kinetics, in ursodeoxycholic acid (UCDA) treated LS; E and F: TGF- β 1 mRNA expression (relative TGF- β 1 expression /mg tissue) during the 21 days follow up kinetics, in LS during the combined treatment, Toco + UCDA. Data are expressed as means \pm SEM (F2-F3 liver samples, $n = 2$; F4 liver samples, $n = 2$). ^k $P < 0.0001$ subject vs control (non-treated); ⁱ $P < 0.001$ subject vs control (non-treated); ^j $P < 0.01$ subject vs control (non-treated), ^h $P < 0.05$ subject vs control (non-treated) (two-way ANOVA test); G and H: Procol1A1 mRNA expression (relative Procol1A1 expression /mg tissue) during the 21 days follow up kinetics, in LS during the combined treatment, Toco + UCDA. Data are expressed as means \pm SEM (F0-F1 liver samples, $n = 10$; F2-F3 liver samples, $n = 2$; F4 liver samples, $n = 2$). ^k $P < 0.0001$ subject vs control (non-treated); ⁱ $P < 0.001$ subject vs control (non-treated); ^j $P < 0.01$ subject vs control (non-treated), ^h $P < 0.05$ subject vs control (non-treated); (two-way ANOVA test); I and J: Triglyceride production (μ g/mg protein) during the 21 days follow-up kinetics, in NINF and hepatitis C virus INF LS from F0-F1 to F4 LS cultures significantly reduced by the combined treatment [Toco + UCDA (UA)], more particularly from day 15 in F4 hepatitis C virus infected LS cultures. Data are expressed as means \pm SEM (F0-F1, $n = 5$, F2-F3 liver samples, $n = 2$; F4 liver samples, $n = 2$). ^k $P < 0.0001$ subject vs control (non-treated); ⁱ $P < 0.001$ subject vs control (non-treated); ^j $P < 0.01$ subject vs control (non-treated), ^h $P < 0.05$ subject vs control (non-treated) (two-way ANOVA test).

ARTICLE HIGHLIGHTS

Research background

Liver fibrosis is frequently associated with viral infection [Hepatitis C virus (HCV) and Hepatitis B virus] infection, chronic inflammation, and excessive alcohol consumption. Despite effective antiviral treatment, morbidity and hepatitis-related mortalities are still increasing. Moreover, the number of non-viral liver diseases such as nonalcoholic steatohepatitis and alcoholic liver disease is steadily growing.

Research motivation

In previous studies, we developed a three dimensional (3D) *ex vivo* model of HCV replication using human liver slice cultures that were followed for 10 days to evaluate a new antiviral drug.

Research objectives

We aimed to establish a 3D *ex vivo* liver slice model viable *in vitro* for 21 days allowing us to examine human liver fibrogenesis by fibrosis inducers and anti-fibrotic therapies.

Research methods

The adult human liver tissue samples from twenty patients were collected after liver resection, and divided into three groups according to their METAVIR score (F): Non-fibrotic F0-F1, obtained during surgery for colorectal cancer liver metastases or fibrotic ranging from F2 to F4. HCV infection, alcohol (ethanol stimulation), and steatosis (palmitate stimulation) were examined in non-fibrotic F0-F1 human liver slices (HLS) compared to fibrotic (F2 to F4) liver slices (FLS) infected (or not) with HCV [Con1/C3 (genotype1b)] (INF). HLS of 350 μ m (2.7×10^6 cells per slice) were cultivated for up to 21 days. At day 0, either ursodeoxycholic acid (only choleric and hepatoprotective properties) and/or α -tocopherol (Toco, anti-oxidant properties which could reduce fibrosis progression) were added to standard of care concentrations on HLS and FLS. The following fibrosis markers expression were assayed in HLS, in FLS and in INF FLS, [tumor growth factor-beta (TGF- β 1), Hsp47, Alpha smooth muscle actin, Procol1A1, Matrix metalloproteinases 2, 9 (MMP-2, 9), Vascular endothelial growth factor] and checked by real-time reverse transcription-quantitative polymerase chain reaction and the triglyceride production by enzyme-linked immunosorbent assay assays.

Research results

Here, for the first time, human LS cultures (stages F0-F4) were successfully maintained and evaluated for 21 days allowing to explore molecular fibrogenesis in more detail including the role of important factors such as HCV infection, ethanol (EtOH), or steatosis, three of the main causes of liver injury in clinical practice. In addition, it was demonstrated that LS cultures are efficient instruments to study anti-fibrotic drugs and their combination. We obtained real-time reverse transcription-quantitative polymerase chain reaction analyses of the biomarkers (TGF- β 1, procol1A1, MMP-2, MMP-9, Alpha smooth muscle actin, HSP47, and Vascular Endothelial Growth Factor) involved in molecular fibrogenesis, and estimation of anti-fibrotic drugs potency, in

both non-fibrotic (F0-F1) and fibrotic livers samples (F2-F3, F4). Expression of the fibrosis biomarkers and the progression to steatosis (estimated by triglyceride production) increased with the addition of HCV and /or EtOH or palmitate. We observed a significant decrease in both of the expression of TGF- β 1, and procollagen1A1 as well as in the production of triglycerides observed in a combined anti-fibrotic treatment applied to the F2-F4 LS cultures infected with HCV.

Research conclusions

The 3D *ex vivo* LS model provides hepatocyte-specific gene expression for 21 days, and effectively reproduces liver fibrogenesis related to HCV infection, EtOH, or lipids exposure, thus, mimicking human viral, alcoholic, and nonalcoholic steatohepatitis liver diseases. Our study is the proof of concept that this relatively easy model can be used to study human liver fibrogenesis of different origins and evaluate the potency of new anti-fibrotic therapies that are currently under development. In particular, this system might estimate unpredictable side effects when testing certain drug combinations.

Research perspectives

Using the *ex vivo* model of human liver slice culture, the perspectives would be to evaluate the potency of new anti-fibrotic therapies alone or in combination and to study the immune components of liver disease.

ACKNOWLEDGEMENTS

The authors are deeply indebted to the patients for their essential contribution to the work. We would like to acknowledge the members of the Departments of Digestive Surgery (Groupe Hospitalier La Pitié Salpêtrière and Groupe Hospitalier Cochin, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France) and the Department of Hepatology (Groupe Hospitalier Cochin, AP-HP, Paris, France), Dr. Jérôme Guéchet (Hôpital Saint-Antoine, Pôle de Biologie Médicale et Pathologie, AP-HP, Paris, France), Dr. Phuong Nhi Bories (Groupe Hospitalier Cochin, Service de Biochimie, AP-HP, Paris, France), the staff of Genomic (GENOM'IC) and Histology (HISTIM) facilities (Cochin Institute, Paris, France) for valuable assistance. We are grateful to Dr. Matthew Albert for the critical reading of the manuscript. Dr. Daria M. Kartasheva-Ebertz received a Ph.D. fellowship from AP-HP, Paris, France.

REFERENCES

- 1 Mehal WZ, Iredale J, Friedman SL. Scraping fibrosis: expressway to the core of fibrosis. *Nat Med* 2011; **17**: 552-553 [PMID: 21546973 DOI: 10.1038/nm0511-552]
- 2 Blachier M, Leleu H, Peck-Radosavljevic M, Valla DC, Roudot-Thoraval F. The burden of liver disease in Europe: a review of available epidemiological data. *J Hepatol* 2013; **58**: 593-608 [PMID: 23419824 DOI: 10.1016/j.jhep.2012.12.005]
- 3 Karsdal MA, Manon-Jensen T, Genovese F, Kristensen JH, Nielsen MJ, Sand JM, Hansen NU, Bay-Jensen AC, Bager CL, Krag A, Blanchard A, Krarup H, Leeming DJ, Schuppan D. Novel insights into the function and dynamics of extracellular matrix in liver fibrosis. *Am J Physiol Gastrointest Liver Physiol* 2015; **308**: G807-G830 [PMID: 25767261 DOI: 10.1152/ajpgi.00447.2014]
- 4 Fabregat I, Moreno-Càceres J, Sánchez A, Dooley S, Dewidar B, Giannelli G, Ten Dijke P; IT-LIVER Consortium. TGF- β signalling and liver disease. *FEBS J* 2016; **283**: 2219-2232 [PMID: 26807763 DOI: 10.1111/febs.13665]
- 5 van Agthoven M, Metselaar HJ, Tilanus HW, de Man RA, IJzermans JN, Martin van Ineveld BM. A comparison of the costs and effects of liver transplantation for acute and for chronic liver failure. *Transpl Int* 2001; **14**: 87-94 [PMID: 11370172 DOI: 10.1007/s001470050852]
- 6 Fisher RL, Vickers AE. Preparation and culture of precision-cut organ slices from human and animal. *Xenobiotica* 2013; **43**: 8-14 [PMID: 23030812 DOI: 10.3109/00498254.2012.728013]
- 7 Westra IM, Oosterhuis D, Groothuis GM, Olinga P. The effect of antifibrotic drugs in rat precision-cut fibrotic liver slices. *PLoS One* 2014; **9**: e95462 [PMID: 24755660 DOI: 10.1371/journal.pone.0095462]
- 8 Olinga P, Schuppan D. Precision-cut liver slices: a tool to model the liver *ex vivo*. *J Hepatol* 2013; **58**: 1252-1253 [PMID: 23336979 DOI: 10.1016/j.jhep.2013.01.009]
- 9 Parrish AR, Gandolfi AJ, Brendel K. Precision-cut tissue slices: applications in pharmacology and toxicology. *Life Sci* 1995; **57**: 1887-1901 [PMID: 7475939 DOI: 10.1016/0024-3205(95)02176-j]
- 10 Wu X, Roberto JB, Knupp A, Kenerson HL, Truong CD, Yuen SY, Brempeles KJ, Tuefferd M, Chen

- A, Horton H, Yeung RS, Crispe IN. Precision-cut human liver slice cultures as an immunological platform. *J Immunol Methods* 2018; **455**: 71-79 [PMID: 29408707 DOI: 10.1016/j.jim.2018.01.012]
- 11 **Lagaye S**, Shen H, Saunier B, Nascimbeni M, Gaston J, Bourdoncle P, Hannoun L, Massault PP, Vallet-Pichard A, Mallet V, Pol S. Efficient replication of primary or culture hepatitis C virus isolates in human liver slices: a relevant ex vivo model of liver infection. *Hepatology* 2012; **56**: 861-872 [PMID: 22454196 DOI: 10.1002/hep.25738]
 - 12 **Lagaye S**, Brun S, Gaston J, Shen H, Stranska R, Camus C, Dubray C, Rousseau G, Massault PP, Courcambek J, Bassisi F, Halfon P, Pol S. Anti-hepatitis C virus potency of a new autophagy inhibitor using human liver slices model. *World J Hepatol* 2016; **8**: 902-914 [PMID: 27478540 DOI: 10.4254/wjh.v8.i21.902]
 - 13 **Poupon R**. Ursodeoxycholic acid and bile-acid mimetics as therapeutic agents for cholestatic liver diseases: an overview of their mechanisms of action. *Clin Res Hepatol Gastroenterol* 2012; **36** Suppl 1: S3-12 [PMID: 23141891 DOI: 10.1016/S2210-7401(12)70015-3]
 - 14 **Chiao TB**, Lee AJ. Role of pentoxifylline and vitamin E in attenuation of radiation-induced fibrosis. *Ann Pharmacother* 2005; **39**: 516-522 [PMID: 15701781 DOI: 10.1345/aph.1E186]
 - 15 **Bedossa P**, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. *Hepatology* 1996; **24**: 289-293 [PMID: 8690394 DOI: 10.1002/hep.510240201]
 - 16 **Pietschmann T**, Kaul A, Koutsoudakis G, Shavinskaya A, Kallis S, Steinmann E, Abid K, Negro F, Dreux M, Cosset FL, Bartenschlager R. Construction and characterization of infectious intragenotypic and intergenotypic hepatitis C virus chimeras. *Proc Natl Acad Sci* 2006; **103**: 7408-7413 [PMID: 16651538 DOI: 10.1073/pnas.0504877103]
 - 17 **Kawano Y**, Cohen DE. Mechanisms of hepatic triglyceride accumulation in non-alcoholic fatty liver disease. *J Gastroenterol* 2013; **48**: 434-441 [PMID: 23397118 DOI: 10.1007/s00535-013-0758-5]
 - 18 **von Hahn T**, McKeating JA. In vitro veritas? *J Hepatol* 2007; **46**: 355-358 [PMID: 17223218 DOI: 10.1016/j.jhep.2006.12.004]
 - 19 **Tzanakakis ES**, Hansen LK, Hu WS. The role of actin filaments and microtubules in hepatocyte spheroid self-assembly. *Cell Motil Cytoskeleton* 2001; **48**: 175-189 [PMID: 11223949 DOI: 10.1002/1097-0169(200103)48:3<175::AID-CM1007>3.0.CO;2-2]
 - 20 **Peshwa MV**, Wu FJ, Follstad, B. D, Cerra, F.B., and Hu, W.S. Kinetics of hepatocyte spheroid formation. *Biotechnol Prog* 1994; **10**: 460-466 [DOI: 10.1021/bp00029a002]
 - 21 **Rueden CT**, Schindelin J, Hiner MC, DeZonia BE, Walter AE, Arena ET, Eliceiri KW. ImageJ2: ImageJ for the next generation of scientific image data. *BMC Bioinformatics* 2017; **18**: 529 [PMID: 29187165 DOI: 10.1186/s12859-017-1934-z]
 - 22 **Crouch SP**, Kozlowski R, Slater KJ, Fletcher J. The use of ATP bioluminescence as a measure of cell proliferation and cytotoxicity. *J Immunol Methods* 1993; **160**: 81-88 [PMID: 7680699 DOI: 10.1016/0022-1759(93)90011-u]
 - 23 **Braydich-Stolle L**, Hussain S, Schlager JJ, Hofmann MC. In vitro cytotoxicity of nanoparticles in mammalian germline stem cells. *Toxicol Sci* 2005; **88**: 412-419 [PMID: 16014736 DOI: 10.1093/toxsci/kfi256]
 - 24 **Bergheim I**, Bode C, Parlesak A. Distribution of cytochrome P450 2C, 2E1, 3A4, and 3A5 in human colon mucosa. *BMC Clin Pharmacol* 2005; **5**: 4 [PMID: 16253141 DOI: 10.1186/1472-6904-5-4]
 - 25 **Podevin P**, Carpentier A, Pène V, Aoudjehane L, Carrière M, Zaïdi S, Hernandez C, Calle V, Méritet JF, Scatton O, Dreux M, Cosset FL, Wakita T, Bartenschlager R, Demignot S, Conti F, Rosenberg AR, Calmus Y. Production of infectious hepatitis C virus in primary cultures of human adult hepatocytes. *Gastroenterology* 2010; **139**: 1355-1364 [PMID: 20600021 DOI: 10.1053/j.gastro.2010.06.058]
 - 26 **Yamaguchi R**, Yano H, Iemura A, Ogasawara S, Haramaki M, Kojiro M. Expression of vascular endothelial growth factor in human hepatocellular carcinoma. *Hepatology* 1998; **28**: 68-77 [PMID: 9657098 DOI: 10.1002/hep.510280111]
 - 27 **Khetani SR**, Bhatia SN. Microscale culture of human liver cells for drug development. *Nat Biotechnol* 2008; **26**: 120-126 [PMID: 18026090 DOI: 10.1038/nbt1361]
 - 28 **Schwarzinger M**, Baillet S, Yazdanpanah Y, Rehm J, Mallet V. Contribution of alcohol use disorders on the burden of chronic hepatitis C in France, 2008-2013: A nationwide retrospective cohort study. *J Hepatol* 2017; **67**: 454-461 [PMID: 28396173 DOI: 10.1016/j.jhep.2017.03.031]
 - 29 **Lee M**, Kowdley KV. Alcohol's effect on other chronic liver diseases. *Clin Liver Dis* 2012; **16**: 827-837 [PMID: 23101984 DOI: 10.1016/j.cld.2012.08.010]
 - 30 **Lefebvre E**, Moyle G, Reshef R, Richman LP, Thompson M, Hong F, Chou HL, Hashiguchi T, Plato C, Poulin D, Richards T, Yoneyama H, Jenkins H, Wolfgang G, Friedman SL. Antifibrotic Effects of the Dual CCR2/CCR5 Antagonist Cenicriviroc in Animal Models of Liver and Kidney Fibrosis. *PLoS One* 2016; **11**: e0158156 [PMID: 27347680 DOI: 10.1371/journal.pone.0158156]
 - 31 **Ratzu V**, de Ledinghen V, Oberti F, Mathurin P, Wartelle-Bladou C, Renou C, Sogni P, Maynard M, Larrey D, Serfaty L, Bonnefont-Rousselot D, Bastard JP, Rivière M, Spénard J, FRESGUN. A randomized controlled trial of high-dose ursodeoxycholic acid for nonalcoholic steatohepatitis. *J Hepatol* 2011; **54**: 1011-1019 [PMID: 21145828 DOI: 10.1016/j.jhep.2010.08.030]
 - 32 **Dufour JF**, Oneta CM, Gonvers JJ, Bihl F, Cerny A, Cereda JM, Zala JF, Helbling B, Steuerwald M, Zimmermann A; Swiss Association for the Study of the Liver. Randomized placebo-controlled trial of ursodeoxycholic acid with vitamin e in nonalcoholic steatohepatitis. *Clin Gastroenterol Hepatol* 2006; **4**: 1537-1543 [PMID: 17162245 DOI: 10.1016/j.cgh.2006.09.025]

- 33 **Hossain N**, Kanwar P, Mohanty SR. A Comprehensive Updated Review of Pharmaceutical and Nonpharmaceutical Treatment for NAFLD. *Gastroenterol Res Pract* 2016; **2016**: 7109270 [PMID: 27006654 DOI: 10.1155/2016/7109270]
- 34 **Konerman MA**, Jones JC, Harrison SA. Pharmacotherapy for NASH: Current and emerging. *J Hepatol* 2018; **68**: 362-375 [PMID: 29122694 DOI: 10.1016/j.jhep.2017.10.015]
- 35 **Younossi ZM**, Ratziu V, Loomba R, Rinella M, Anstee QM, Goodman Z, Bedossa P, Geier A, Beckebaum S, Newsome PN, Sheridan D, Sheikh MY, Trotter J, Knapple W, Lawitz E, Abdelmalek MF, Kowdley KV, Montano-Loza AJ, Boursier J, Mathurin P, Bugianesi E, Mazzella G, Oliveira A, Cortez-Pinto H, Graupera I, Orr D, Gluud LL, Dufour JF, Shapiro D, Campagna J, Zaru L, MacConell L, Shringarpure R, Harrison S, Sanyal AJ; REGENERATE Study Investigators. Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial. *Lancet* 2019; **394**: 2184-2196 [PMID: 31813633 DOI: 10.1016/S0140-6736(19)33041-7]
- 36 **Ratziu V**. Novel Pharmacotherapy Options for NASH. *Dig Dis Sci* 2016; **61**: 1398-1405 [PMID: 27003143 DOI: 10.1007/s10620-016-4128-z]
- 37 **Friedman SL**, Ratziu V, Harrison SA, Abdelmalek MF, Aithal GP, Caballeria J, Francque S, Farrell G, Kowdley KV, Craxi A, Simon K, Fischer L, Melchor-Khan L, Vest J, Wiens BL, Vig P, Seyedkazemi S, Goodman Z, Wong VW, Loomba R, Tacke F, Sanyal A, Lefebvre E. A randomized, placebo-controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis. *Hepatology* 2018; **67**: 1754-1767 [PMID: 28833331 DOI: 10.1002/hep.29477]
- 38 **Sato K**, Gosho M, Yamamoto T, Kobayashi Y, Ishii N, Ohashi T, Nakade Y, Ito K, Fukuzawa Y, Yoneda M. Vitamin E has a beneficial effect on nonalcoholic fatty liver disease: a meta-analysis of randomized controlled trials. *Nutrition* 2015; **31**: 923-930 [PMID: 26059365 DOI: 10.1016/j.nut.2014.11.018]



Published by **Baishideng Publishing Group Inc**
7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Telephone: +1-925-3991568

E-mail: bpgoffice@wjgnet.com

Help Desk: <https://www.f6publishing.com/helpdesk>

<https://www.wjgnet.com>

